Bracco

Italy - Milan

Biotechnology

Website LinkedIn Careers Page

Focus: Imaging

Bracco is a life sciences company focused on Imaging.

CardiovascularGastroenterologyHematology

Employees

1001-5000

Open Jobs

0

Products & Portfolio (26)

24 discontinued products not shown

rubidium chloride rb-82

LOE Approaching

INJECTION · INJECTABLE

82 is analogous to potassium ion (K) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. Rb participates in the sodium-potassium (Na/K) ion exchange pumps that are present in cell membranes. The intracellular uptake of Rb 82 requires maintenance of ionic gradient across cell membranes. Rb 82 radioactivity is increased in viable myocardium reflecting intracellular retention, while the tracer is cleared from necrotic or infarcted tissue.

LOE Approaching

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY Mebrofenin is an iminodiacetic acid (HIDA) derivative with no known pharmacologic action at the recommended doses. Following intravenous administration in normal subjects, Technetium Tc 99m Mebrofenin was rapidly cleared from the circulation. The mean percent injected dose remaining in the blood at 10 minutes was 17%. The injected activity was cleared through the hepatobiliary system with visualization of the liver by 5 minutes and maximum liver uptake occurring at 11 minutes post-injection. Hepatic duct and gallbladder visualization occurred by 10 to 15 minutes and intestinal activity was visualized by 30 to 60 minutes in subjects with normal hepatobiliary function. The mean percent injected dose excreted in the urine during the first 3 hours was 1% (0.4 to 2.0%). Elevated serum bilirubin levels increase renal excretion of Tc 99m HIDA agents. In two studies in which Tc 99m Mebrofenin was administered to patients having mean elevated serum bilirubin levels of 9.8 mg/dL (1.7 to 46.3 mg/dL), the mean percent injected dose excreted in the urine during the first 3 hours was 3% (0.2 to 11.5%). The mean percent injected dose excreted in the urine during 3-24 hours was 14.9% (0.4 to 34.8%). In jaundiced patients, the percent injected dose remaining in the blood at 10 minutes may be twice as high or more than the level in normals. Hepatobiliary transit may be delayed and visualization times increased. As a consequence, the quality of the images obtained frequently diminishes.

diatrizoate meglumine

LOE Approaching

URETHRAL · SOLUTION

CYSTOGRAFIN DILUTE

diatrizoate meglumine

LOE Approaching

URETHRAL · SOLUTION

X-Ray Contrast Activity

ORAL · FOR SUSPENSION

X-Ray Contrast Activity

ORAL · FOR SUSPENSION

X-Ray Contrast Activity

ORAL · SUSPENSION

X-Ray Contrast Activity

diatrizoate meglumine and diatrizoate sodium

LOE Approaching

ORAL, RECTAL · SOLUTION

CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological effects. Diatrizoate meglumine and diatrizoate sodium exert a mild laxative effect attributable to their high osmolarity. Diatrizoate meglumine and diatrizoate sodium are sparingly absorbed from the intact gastrointestinal tract, and therefore permit gastrointestinal opacification and delineation after oral or rectal administration. Oral administration is used for radiographic evaluation of the esophagus, stomach and proximal small intestine. Rectal administration is used for examination of the colon; however, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution of the medium. Enough absorption from the gastrointestinal tract to permit incidental visualization of the urinary tract has been reported; this should also be considered when thyroid testing is being contemplated, since iodine-mediated thyrotropic effects may occur (see ).

LOE Approaching

INJECTION · INJECTABLE

X-Ray Contrast Activity

LOE Approaching

INJECTION · INJECTABLE

X-Ray Contrast Activity

LOE Approaching

INJECTION · INJECTABLE

X-Ray Contrast Activity

View all 26 products

Pipeline & Clinical Trials

Reading glass

N/A

Clinical Trials (1)

NCT03719196Reading Glass on Livelihoods and Quality of Life in Rural Bangladesh

N/A

CHV-NEO

N/A

Clinical Trials (1)

NCT05187897CHV-NEO: Community-based Digital Communication to Support Neonatal Health

N/A

Homestead Food Production program

N/A

Iron fortified lentils

Anemia, Iron-Deficiency

N/A

Clinical Trials (1)

NCT03516734Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh

N/A

Presbyopia screening training

N/A

Clinical Trials (1)

NCT03001258Presbyopia Screening by Community Health Worker in Bangladesh

N/A

Balanced energy and protein supplement for pregnant women

Fetal Growth Retardation

N/A

Clinical Trials (1)

NCT05576207BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)

N/A

Glasses to correct presbyopia

N/A

Clinical Trials (1)

NCT05510687Transforming Households With Refraction and Innovative Financial Technology

N/A

Integrated child stimulation, nutrition, lead, arsenic, WASH intervention

Early Childhood Development

N/A

Clinical Trials (1)

NCT04111016Feasibility of Implementing RINEW Through the Government System

N/A

Behavioural change modification, Screening, NCD related knowledge practice and attitude

N/A

Clinical Trials (1)

NCT06453382Development and Testing of a Sub-district Specific Model of 'Whole-of-government', and 'Whole-of-society' Approaches for the Prevention and Control of Non-communicable Diseases in a Sub-district of Bangladesh

N/A

Handwashing stations at the public places and no soap

Hygiene Practices and Knowledge

N/A

Clinical Trials (1)

NCT04753645BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition

N/A

Child feeding counselling, food voucher, micronutrient powder, WASH

Child Malnutrition

N/A

Clinical Trials (1)

NCT03641001Nutrition Intervention Integrated With Food Voucher to Improve Child Growth and Feeding Practices

N/A

Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia

Febrile Illness

N/A

Clinical Trials (1)

NCT04478578Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia

N/A

Low-Sodium Salt Substitute

N/A

Clinical Trials (1)

NCT05425030A Community Health Worker-Led LSSS Intervention in Bangladesh

N/A

Low Intensity Nudges

N/A

Clinical Trials (1)

NCT04765540The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh

N/A

Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia

Acute Febrile Illness

N/A

Clinical Trials (1)

NCT04629053Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia

N/A

Intervention-group

Zinc Deficiency

N/A

Clinical Trials (1)

NCT03079583The Efficacy of Zinc-biofortified Rice in Bangladeshi Children

N/A

5A-5R-based counselling session

Tobacco Use Cessation

N/A

Clinical Trials (1)

NCT06501209Evaluation of the Effectiveness of 5A-5R Counselling Services for Tobacco Cessation

N/A

Multicomponent decentralized care

Phase 1

Clinical Trials (1)

NCT06258473Addressing Gaps in the Hypertension and Diabetes Care Continuum in Rural Bangladesh: The Dinajpur Study

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1927

Portfolio: 73 approved products, 17 clinical trials

Top TAs: Gastroenterology

Portfolio Health

Launch1 (1%)

Growth2 (3%)

Peak14 (19%)

LOE Approaching55 (75%)

Post-LOE1 (1%)

73 total products

Therapeutic Area Focus

Gastroenterology

1 marketed

Marketed

Pipeline

Hiring Trend

Stable

0

Open Roles

+0

Added

-0

Filled/Removed

Based on last 4 crawl cycles